Conditions: Non-small Cell Lung Cancer
Keywords: Lung Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 84
Healthy volunteers: no

Brief summary:
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: carboplatin intervention 2: paclitaxel intervention 3: sunitinib
Intervention descriptions: intervention 1: AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices. intervention 2: 175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices. intervention 3: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).

Protocol document: